Safety and Effectiveness of TactiFlex Ablation Catheter Sensor Enabled (TactiFlex SE) for the Treatment of Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation (TactiFlex PAF IDE Trial)

Brief description of study

The purpose of this research study is to demonstrate that the TactiFlex SE catheter is safe and effective for ablating your symptomatic, paroxysmal atrial fibrillation (PAF) that is not effectively treated with medication. Data collected for this study will be submitted for review and approval by the U.S. Food and Drug Administration (FDA) and may be submitted to regulatory agencies in other geographies such as the European Union, Australia and/or Canada.


Clinical Study Identifier: s20-01218
ClinicalTrials.gov Identifier: NCT04356040


If you are registered as a volunteer, please login to the dashboard to send referrals.